In a comprehensive report by the Wall Street Journal, a spotlight has been cast on the behavior of Elon Musk, CEO of SpaceX and Tesla, with board members expressing unease over his rumored use of illegal drugs. The investigation delves into Musk’s association with LSD, cocaine, ecstasy, and psychedelic mushrooms, raising concerns about the potential ramifications for his influential role in leading major companies.
Elon Musk, known for his dynamic and sometimes unpredictable behavior, has often attributed it to the immense stress and sleepless nights associated with overseeing six significant companies, including Tesla, SpaceX, and the social media platform X (formerly Twitter). However, a recent Wall Street Journal report suggests an additional layer to Musk’s behavior – his reported use of illegal drugs.
The report outlines Musk’s alleged consumption of substances such as LSD, cocaine, ecstasy, and psychedelic mushrooms during private gatherings around the world. Notably, attendees at these events are bound by non-disclosure agreements and are required to surrender their phones before entering, emphasizing the secrecy surrounding Musk’s recreational activities.
While Tesla board members have informally discussed Musk’s reported drug use, no formal concerns have been documented in official board agendas or meeting minutes. It’s revealed that several directors, including current chairman Robyn Denholm, have approached Musk’s brother, Kimbal Musk, seeking assistance in managing Musk’s behavior without explicitly mentioning the term “drugs.”
The report also raises questions about Musk’s state during significant events, such as his infamous marijuana-smoking episode during the Joe Rogan podcast in 2018. This incident drew criticism from NASA, prompting demands for written assurances from SpaceX that the company adhered to the federal Drug-Free Workplace Act.
Furthermore, there are indications that Musk may have been under the influence of drugs when he tweeted about taking Tesla private in 2018. This particular tweet triggered an SEC investigation, resulting in a $40 million fine and Musk’s resignation as Tesla’s chairman.
One notable revelation is the departure of former Tesla director Linda Johnson Rice in 2019, reportedly due to frustrations with Musk’s behavior and concerns about his alleged drug use.
As the report surfaces, it underscores the potential implications of Musk’s behavior and alleged drug use on the six major companies under his leadership, raising questions about governance and the impact on billions of dollars in assets. The story prompts a critical examination of the delicate balance between the personal conduct of influential figures and the responsibilities tied to their leadership roles.
